Omalizumab costs £8,056 INNOVATE() £8,455 IA-05 EUP() (per year) IA-05 EUP () Administration INNOVATE () First year: £260 First year: £268 NHS and monitoring NHS reference Thereafter: £146 Thereafter: £151 reference costs () costs () S3 Model inputs for maintenance OCS subgroup Adults and adolescents (patients 12 years) ≥ Variables Value Source Baseline annual rate of exacerbations 0.9735 INNOVATE CSNS (0.6410 to maintenance exacerbations 1.4784) OCS () 1.000 INNOVATE CSS (0.4493 to maintenance exacerbations 2.2259) OCS () 46.94% INNOVATE Proportion of (32.97% to maintenance responders 60.91%) OCS () Risk ratio for 0.4142 INNOVATE CSNS (0.1569 to maintenance exacerbations 1.0938) OCS () (responders)
Omalizumab costs (per year) £8,056 INNOVATE() £8,455 IA-05 EUP() Administration and monitoring First year: £260 Thereafter: £146 INNOVATE () NHS reference costs () First year: £268 Thereafter: £151 IA-05 EUP () NHS reference costs () S3 Model inputs for maintenance OCS subgroup Adults and adolescents (patients ≥ 12 years) Variables Value Source Baseline annual rate of exacerbations CSNS exacerbations 0.9735 (0.6410 to 1.4784) INNOVATE maintenance OCS () CSS exacerbations 1.000 (0.4493 to 2.2259) INNOVATE maintenance OCS () Proportion of responders 46.94% (32.97% to 60.91%) INNOVATE maintenance OCS () Risk ratio for CSNS exacerbations (responders) 0.4142 (0.1569 to 1.0938) INNOVATE maintenance OCS ()
1-s2.0-S1098301514019330-mmc1.docx